Jacob Garcia

发表

Reply to Barroso-Sousa R et al.

P. K. Morrow, Jacob Garcia, L. Green, 2017, Breast.

Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma

L. Matza, D. Maloney, A. Powers, 2022, PharmacoEconomics - Open.

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Michael L. Wang, L. Gordon, D. Maloney, 2017 .

CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).

Michael L. Wang, L. Gordon, C. Sutherland, 2017 .

Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care

Tina M. Albertson, M. Gitlin, S. Snyder, 2021, Advances in Therapy.

Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer

G. Lyman, P. Fox, D. Patt, 2018, Clinical breast cancer.

Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use.

G. Lyman, S. Mhatre, D. Weycker, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review

G. Lyman, D. Weycker, M. Reiner, 2017, Supportive Care in Cancer.

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.

A. Nguyen, T. Siddiqi, J. Abramson, 2021, Blood advances.

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer

G. Lyman, D. Patt, J. Crawford, 2019, Supportive Care in Cancer.

Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor

G. Lyman, D. Weycker, S. Tzivelekis, 2017, Supportive Care in Cancer.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Michael L. Wang, L. Gordon, D. Maloney, 2020, The Lancet.

Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.

D. Patrick, D. Maloney, A. Powers, 2021, Blood advances.

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.

G. Lyman, D. Patt, L. Asmar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

Michael L. Wang, L. Gordon, D. Maloney, 2018 .

Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1

G. Salles, P. Spin, Yeonhee Kim, 2021, Advances in Therapy.

NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim

J. Kirshner, C. Maxwell, P. K. Morrow, 2017, Supportive Care in Cancer.

“Same-Day” administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale

B. Sherif, J. Kaye, S. Tzivelekis, 2016, Supportive Care in Cancer.

The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy

M. Bonafede, R. Maziarz, J. Tkacz, 2020, Leukemia & lymphoma.

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Michael L. Wang, L. Gordon, D. Maloney, 2019, Blood.

Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review

M. Samuel, R. Barron, Xiaoyan Li, 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

High Durable CR Rates and Preliminary Safety Profile for JCAR017 in R/R Aggressive B-NHL (TRANSCEND NHL 001 Study): A Defined Composition CD19-Directed CAR T Cell Product with Potential for Outpatient Administration

Michael L. Wang, L. Gordon, D. Maloney, 2018 .

High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration.

Michael L. Wang, L. Gordon, D. Maloney, 2018 .

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice

D. Weycker, A. Kartashov, R. Barron, 2015, Supportive Care in Cancer.

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

D. Patrick, D. Maloney, A. Powers, 2019, Blood.

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

Michael L. Wang, L. Gordon, D. Maloney, 2017 .

SAFETY AND PRELIMINARY EFFICACY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA RECEIVING LISOCABTAGENE MARALEUCEL IN TRANSCEND NHL 001

L. Gordon, T. Farazi, M. Lunning, 2019, Blood.

Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001.

Michael L. Wang, L. Gordon, D. Maloney, 2019, Journal of Clinical Oncology.